SEOM guidelines for the management of Malignant Melanoma 2015

被引：5

作者：

Berrocal, A. ^{[1
]}

Arance, A. ^{[2
]}

Espinosa, E. ^{[3
]}

Castano, A. G. ^{[4
]}

Cao, M. G. ^{[5
]}

Larriba, J. L. G. ^{[6
]}

Martin, J. A. L. ^{[7
]}

Marquez, I. ^{[8
]}

Soria, A. ^{[9
]}

Algarra, S. M. ^{[10
]}

机构：

[1] Univ Valencia, Med Oncol Serv, Consorcio Hosp Gen, Avda Tres Cruces 2, Valencia 46014, Spain

[2] Hosp Clin Barcelona, Barcelona, Spain

[3] Hosp Univ La Paz, Madrid, Spain

[4] Hosp Univ Marques Valdecilla, Santander, Spain

[5] Hosp Univ Quiron Dexeus, Barcelona, Spain

[6] Hosp Univ Clin San Carlos, Madrid, Spain

[7] Hosp Univ 12 Octubre, Madrid, Spain

[8] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[9] Hosp Univ Ramon & Cajal, Madrid, Spain

[10] Univ Navarra Clin, Pamplona, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2015年 / 17卷 / 12期

关键词：

Melanoma; Metastatic; Adjuvant; Immunotherapy; b-raf; COOPERATIVE-ONCOLOGY-GROUP; HIGH-RISK MELANOMA; ADJUVANT THERAPY; CUTANEOUS MELANOMA; POOLED ANALYSIS; OPEN-LABEL; BRAF; INTERFERON; DABRAFENIB; IPILIMUMAB;

D O I：

10.1007/s12094-015-1450-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

All melanoma patients must be confirmed histologically and resected according to Breslow. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon must be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 therapy. Up to 10 years follow up is recommended for melanoma patients with dermatologic examinations and physical exams.

引用

页码：1030 / 1035

页数：6

共 50 条

[31] Short guidelines - Malignant melanoma of the skin
Garbe, Claus
Schadendorf, Dirk
Stolz, Wilhelm
Volkenandt, Matthias
Reinhold, Uwe
Kortmann, Rolf-Dieter
Kettelhack, Christoph
Frerich, Bernhard
Keilholz, Ulrich
Dummer, Reinhard
Sebastian, Guenther
Tilgen, Wolfgang
Schuler, Gerold
Mackensen, Andreas
Kaufmann, Roland
Hauschild, Axel
[J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2008, 6 : S9 - S15
[32] GUIDELINES OF CARE FOR MALIGNANT-MELANOMA
DRAKE, LA
CEILLEY, RI
CORNELISON, RL
DOBES, WL
DORNER, WA
GOLTZ, RW
LEWIS, CW
SALASCHE, SJ
TURNER, MLC
TURNER, MLC
ARROWSMITH, DR
CATALANO, PM
DAY, CL
LEWIS, CW
SOBER, AJ
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1993, 28 (04) : 638 - 641
[33] THE MANAGEMENT OF MALIGNANT MELANOMA
ROYSTER, HP
BAKER, LM
[J]. ANNALS OF SURGERY, 1957, 145 (06) : 888 - 892
[34] Management of malignant melanoma
Kroon, BBR
Nieweg, OE
[J]. ANNALES CHIRURGIAE ET GYNAECOLOGIAE, 2000, 89 (03) : 242 - 250
[35] Management of Malignant Melanoma
Mun, Goo-Hyun
[J]. ARCHIVES OF PLASTIC SURGERY-APS, 2012, 39 (05): : 565 - 574
[36] MANAGEMENT OF MALIGNANT MELANOMA
GREEN, A
[J]. BRITISH MEDICAL JOURNAL, 1964, 2 (541): : 1200 - &
[37] SEOM clinical guidelines (2021)
Ana Fernández Montes
Enriqueta Felip Font
[J]. Clinical and Translational Oncology, 2022, 24 : 611 - 612
[38] SEOM guidelines 2016: an update
Santaballa, A.
Martin, M.
[J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (12): : 1161 - 1162
[39] SEOM guidelines for endometrial cancer
Oaknin, Ana
Rodriguez-Freixinos, Victor
Diaz de Corcuera, Isabela
Rivera, Fernando
Maria del Campo, Jose
[J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (07): : 512 - 515
[40] SEOM guidelines for cervical cancer
A. Oaknin
M. J. Rubio
A. Redondo
A. De Juan
J. F. Cueva Bañuelos
M. Gil-Martin
E. Ortega
A. Garcia-Arias
A. Gonzalez-Martin
I. Bover
[J]. Clinical and Translational Oncology, 2015, 17 : 1036 - 1042

← 1 2 3 4 5 →